SERPINE1 (Serpin Family E Member 1)

Knockdown of SERPINE1 in HNSC cell lines led to marked inhibition of both proliferation and colony formation. The findings demonstrate the critical involvement of CEGs in HNSC progression and immune modulation, and proposes a novel three-gene signature as a robust prognostic biomarker and potential guide for individualized therapy.

Consistent with analysis of TCGA-CRC, positive correlation can be detected between VAX2 and SERPINE1 in fresh CRC samples. Thus, VAX2-SERPINE1 axis participate in CRC progression and work as a potential target against CRC.

This integrative multi-omics analysis elucidates the complex molecular architecture underlying BaP-induced toxicity in HNSC, establishing SERPINE1 and STK3 as promising prognostic biomarkers and potential therapeutic targets. Our findings provide mechanistic insights into environmental carcinogen-mediated HNSC pathogenesis and offer a rational framework for developing precision medicine approaches targeting BaP-associated malignancies.

Our study illuminates how SERPINE1, often overexpressed in CRC, leverages the p38/MAPK pathway to bolster cuproptosis resistance and angiogenesis, offering a promising avenue for anti-angiogenic strategies in CRC treatment.

Furthermore, curcumin significantly inhibited tumor growth (p=0.039) and exhibited a synergistic antitumor effect with oxaliplatin in vivo. This study comprehensively elucidates the molecular mechanisms by which curcumin exerts its therapeutic effects in CRC via modulation of ferroptosis and Wnt/β-catenin signaling pathway. These findings provide novel mechanistic insights and support the translational potential of curcumin in preclinical and clinical frameworks.

This study is the first to analyze the regulatory network of palmitoylation in HCC epithelial cells by combining single-cell and bulk transcriptomes, providing new molecular targets and methodological references for HCC prognosis evaluation and precision therapy.

Our findings suggest CSRS score and its constituent genes represent potential biomarkers for prognosis and immunotherapeutic benefit in COAD patients. Extending this nine-gene set into a broader senescence-associated panel should be a next step toward delivering truly individualized treatment plans.

Structure-based molecular docking further identified Lenvatinib and Dasatinib as previously unappreciated candidate inhibitors of SERPINE1, suggesting actionable therapeutic opportunities. Its strong prognostic power, combined with newly revealed druggability, positions SERPINE1 as a tractable therapeutic axis for precision immunotherapy and rational drug repurposing. These findings provide a mechanistically grounded and clinically actionable entry point into targeting the inflammatory tumor microenvironment of pancreatic cancer.

The SIS signature contributes to HNSCC progression, stemness, and drug resistance by facilitating CAF generation. Ovatodiolide disrupts this signature and inhibits CAF transformation.

This study provides new insights into the molecular mechanisms underlying the progression of GBM, emphasizing the role of SERPINE1 and its interaction with NR4A1 in promoting EMT and tumor invasion. Inhibiting the expression of SERPINE1 in GBM cells can prevent cell invasion, providing a potential strategy for the treatment of GBM.

qPCR analysis revealed that the significant expressions of SPARC, EFEMP1, RGS5 and SERPINE1 were significantly upregulated in gastric cancer tissues compared to the normal tissues. Our study provides insights into the composition of the tumor microenvironment and construction of a four-gene CAF signature associated with clinical prognosis, offering new perspectives for the clinical management of gastric cancer.

Chemotherapy intensified senescence in hepatocytes by 5-fold relative to aging and led to unique CDKN2A+ populations. Across conditions, senescent cells shared AP-1 activation, pro-inflammatory cytokines, and apoptosis resistance, suggesting therapeutic opportunities.